289 related articles for article (PubMed ID: 28260043)
1. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
2. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
Yu M; Zou Q; Wu X; Han G; Tong X
Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
[TBL] [Abstract][Full Text] [Related]
3. Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting Snail expression in hepatocellular carcinoma.
Yang Y; Zhang N; Zhu J; Hong XT; Liu H; Ou YR; Su F; Wang R; Li YM; Wu Q
Int J Oncol; 2017 Jun; 50(6):1977-1988. PubMed ID: 28498415
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA AK021443 Promotes Cell Proliferation and Migration by Regulating Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.
Yang J; Li J; Liu B; Zhang R; Gu F; Zhao J; Cheng S
DNA Cell Biol; 2018 May; 37(5):481-490. PubMed ID: 29638164
[TBL] [Abstract][Full Text] [Related]
5. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
[TBL] [Abstract][Full Text] [Related]
6. TALEN-induced disruption of Nanog expression results in reduced proliferation, invasiveness and migration, increased chemosensitivity and reversal of EMT in HepG2 cells.
Yu AQ; Ding Y; Li CL; Yang Y; Yan SR; Li DS
Oncol Rep; 2016 Mar; 35(3):1657-63. PubMed ID: 26676719
[TBL] [Abstract][Full Text] [Related]
7. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of miR-200a suppresses epithelial-mesenchymal transition of liver cancer stem cells.
Wang J; Yang X; Ruan B; Dai B; Gao Y; Duan J; Qu S; Tao K; Dou K; Li H
Tumour Biol; 2015 Apr; 36(4):2447-56. PubMed ID: 25412960
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-1277 Inhibits Proliferation and Migration of Hepatocellular Carcinoma HepG2 Cells by Targeting and Suppressing BMP4 Expression and Reflects the Significant Indicative Role in Hepatocellular Carcinoma Pathology and Diagnosis After Magnetic Resonance Imaging Assessment.
Cao X; Xu L; Liu Q; Yang L; Li N; Li X
Oncol Res; 2019 Feb; 27(3):301-309. PubMed ID: 29562958
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA NRON is downregulated in HCC and suppresses tumour cell proliferation and metastasis.
Yao Z; Xiong Z; Li R; Liang H; Jia C; Deng M
Biomed Pharmacother; 2018 Aug; 104():102-109. PubMed ID: 29772429
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
14. Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
Wu Q; Wang X; Liu J; Zheng J; Liu Y; Li Y; Su F; Ou W; Wang R
Oncol Rep; 2016 Sep; 36(3):1325-32. PubMed ID: 27430152
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-induced epithelial-mesenchymal transition through SEMA 4A in hepatocellular carcinoma.
Pan JX; Wang F; Ye LY
Biochem Biophys Res Commun; 2016 Oct; 479(4):610-614. PubMed ID: 27697528
[TBL] [Abstract][Full Text] [Related]
17. The role of miR-99b in mediating hepatocellular carcinoma invasion and migration.
Liu CJ; Yang JH; Huang FZ; Yang JH; Liu CP; Mao XH; Yi WM; Shen XB; Peng C; Chen MF; Jiang B; Wu JS
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2273-2281. PubMed ID: 29762829
[TBL] [Abstract][Full Text] [Related]
18. PEG10 is imperative for TGF-β1-induced epithelial‑mesenchymal transition in hepatocellular carcinoma.
Zhang M; Sui C; Dai B; Shen W; Lu J; Yang J
Oncol Rep; 2017 Jan; 37(1):510-518. PubMed ID: 28004118
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
